CDK9 is a novel prognostic marker and therapeutic target in ovarian cancer, osteosarcoma and leukaemia.16,36,47 Our findings also suggest that CDK9 may serve as a novel diagnostic marker of NSCLC. This evidence concerns the gene CDK9 and ovarian carcinoma.